Literature DB >> 857172

Formation of chlorpromazine sulphoxide and monodesmethylchlorpromazine by microsomes of small intestine.

R Knoll, W Christ, B Müller-Oerlinghausen, H Coper.   

Abstract

The metabolism of chlorpromazine by microsomal preparations of the small intestine from guinea pig and rat was studied. 35S-chlorpromazine was incubated with these preparations in Krebs-Ringer bicarbonate buffer at 37 degrees C. Control values were obtained by performing the assay at 0 degrees C. The metabolites were extracted with dichloroethane and separated by TLC. In incubations with intestinal microsomes from guinea pigs chlorpromazine sulphoxide and monodesmethyl chlorpromazine were identified as main metabolites. The apparent Michaelis constant for sulphoxidation of chlorpromazine is approximately 20-30 micronM and for N-demethylation in the range of 30-100 micronM. Using microsomal preparations from rat intestine, however, noteworthy formation of chlorpromazine metabolites could not be found. This observation can be explained by the fact that the cytochrome P450 content of rat intestinal microsomes was extremely low compared with that determined in guinea pig microsomes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 857172     DOI: 10.1007/BF00499931

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

Review 1.  Metabolism of hormones, drugs and other substances by the gut.

Authors:  K Hartiala
Journal:  Physiol Rev       Date:  1973-04       Impact factor: 37.312

2.  Metabolism of the phenothiazine drug perazine by liver and lung microsomes from various species.

Authors:  U Breyer
Journal:  Biochem Pharmacol       Date:  1971-12       Impact factor: 5.858

3.  [Metabolism of perazine in vitro].

Authors:  U Breyer
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1970

4.  Properties of benzpyrene hydroxylase in the liver, intestinal mucosa and adrenal of untreated and 3-methylcholanthrene-treated rats.

Authors:  N G Zampaglione; G J Mannering
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

5.  Thin-layer chromatography of chlorpromazine metabolites. Attempt to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics.

Authors:  P Turano; W J Turner; A A Manian
Journal:  J Chromatogr       Date:  1973-01-17

6.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

7.  Starvation and phenobarbital treatment effects on drug hydroxylation and glucuronidation in the rat liver and small intestinal mucosa.

Authors:  M Marselos; M Laitinen
Journal:  Biochem Pharmacol       Date:  1975-08-15       Impact factor: 5.858

8.  Phenobarbital inducible drug monooxygenase activity in the small intestine of mice.

Authors:  C Lehrmann; V Ullrich; W Rummel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

9.  In vitro induction by phenobarbital of drug monooxygenase activity in mouse isolated small intestine.

Authors:  R Scharf; V Ullrich
Journal:  Biochem Pharmacol       Date:  1974-08       Impact factor: 5.858

10.  Destruction of chlorpromazine during absorption in the rat in vivo and in vitro.

Authors:  S H Curry; A D'Mello; G P Mould
Journal:  Br J Pharmacol       Date:  1971-07       Impact factor: 8.739

View more
  2 in total

1.  Effect of entekohepatic circulation on the pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; U von Grodzicki; U Hirschberger; H Rennekamp
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

2.  Phase I metabolism of imipramine by microsomes of small intestine in comparison with metabolism by liver microsomes.

Authors:  W Christ; W Hecker; H Junge; G Stille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.